Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/14257
標題: 犬肥大細胞瘤臨床及病理特徵與KIT蛋白表現或c-kit基因突變間之關聯性
Association between clinicopathologic characteristics and KIT expression or c-kit mutation in canine mast cell tumors
作者: 蔡欣亞
Tsai, Hsin-Ya
關鍵字: dogs

MCTs
KIT
cytology:histololy
prognosis
肥大細胞瘤
細胞學:組織病理學:預後分析.KIT
出版社: 獸醫學系暨研究所
引用: Abadie, J.J., Amardeilh, M.A., Delverdier, M.E., 1999. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc 215, 1629-1634. Abraham, S.N., Malaviya, R., 1997. Mast cells in infection and immunity. Infect Immun 65, 3501-3508. Akin, C., Metcalfe, D.D., 2004. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114, 13-19; quiz 20. Al-Muhsen, S.Z., Shablovsky, G., Olivenstein, R., Mazer, B., Hamid, Q., 2004. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy 34, 911-916. Arber, D.A., Tamayo, R., Weiss, L.M., 1998. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 29, 498-504. Baker-Gabb, M., Hunt, G.B., France, M.P., 2003. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery. Aust Vet J 81, 732-738. Besmer, P., Murphy, J.E., George, P.C., Qiu, F.H., Bergold, P.J., Lederman, L., Snyder, H.W., Jr., Brodeur, D., Zuckerman, E.E., Hardy, W.D., 1986. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320, 415-421. Bettini, G., Morini, M., Marcato, P.S., 2003. Gastrointestinal spindle cell tumours of the dog: histological and immunohistochemical study. J Comp Pathol 129, 283-293. Blechman, J.M., Lev, S., Barg, J., Eisenstein, M., Vaks, B., Vogel, Z., Givol, D., Yarden, Y., 1995. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80, 103-113. Bostock, D.E., 1973. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 14, 27-41. Bostock, D.E., 1986. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 142, 1-19. Bostock, D.E., Crocker, J., Harris, K., Smith, P., 1989. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer 59, 915-918. Braconi, C., Bracci, R., Cellerino, R., 2008. Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets 8, 359-366. Brodey, R.S., 1970. Canine and feline neoplasia. Adv Vet Sci Comp Med 14, 309-354. Broudy, V.C., 1997. Stem cell factor and hematopoiesis. Blood 90, 1345-1364. Broudy, V.C., Lin, N.L., Sabath, D.F., 2001. The fifth immunoglobulin-like domain of the Kit receptor is required for proteolytic cleavage from the cell surface. Cytokine 15, 188-195. Buchdunger, E., O''Reilly, T., Wood, J., 2002. Pharmacology of imatinib (STI571). Eur J Cancer 38 Suppl 5, S28-36. Butnor, K.J., Burchette, J.L., Sporn, T.A., Hammar, S.P., Roggli, V.L., 2004. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 128, 538-543. Cahalane, A.K., Payne, S., Barber, L.G., Duda, L.E., Henry, C.J., Mauldin, G.E., Frimberger, A.E., Cotter, S.M., Moore, A.S., 2004. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). J Am Vet Med Assoc 225, 401-408. Cairoli, R., Grillo, G., Beghini, A., Cornacchini, G., Larizza, L., Morra, E., 2004. Chronic myelogenous leukemia with acquired c-kit activating mutation and transient bone marrow mastocytosis. Hematol J 5, 273-275. Camps-Palau, M.A., Leibman, N.F., Elmslie, R., Lana, S.E., Plaza, S., McKnight, J.A., Risbon, R., Bergman, P.J., 2007. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Vet Comp Oncol 5, 156-167. Chabot, B., Stephenson, D.A., Chapman, V.M., Besmer, P., Bernstein, A., 1988. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335, 88-89. Chaffin, K., Thrall, D.E., 2002. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Vet Radiol Ultrasound 43, 392-395. Cohen, D., Reif, J.S., Brodey, R.S., Keiser, H., 1974. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 34, 2859-2868. Cooper, M., Tsai, X., Bennett, P., 2009. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Vet Comp Oncol 7, 196-206. Corless, C.L., Fletcher, J.A., Heinrich, M.C., 2004. Biology of gastrointestinal stromal tumors. J Clin Oncol 22, 3813-3825. Curtin, J.A., Busam, K., Pinkel, D., Bastian, B.C., 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24, 4340-4346. Davis, B.J., Page, R., Sannes, P.L., Meuten, D.J., 1992. Cutaneous mastocytosis in a dog. Vet Pathol 29, 363-365. Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M., Fletcher, J.A., Silverman, S.G., Silberman, S.L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B.J., Corless, C., Fletcher, C.D., Joensuu, H., 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347, 472-480. Denerolle, P., White, S.D., Taylor, T.S., Vandenabeele, S.I., 2007. Organic diseases mimicking acral lick dermatitis in six dogs. J Am Anim Hosp Assoc 43, 215-220. Dobson, J., Cohen, S., Gould, S., 2004. Treatment of canine mast cell tumours with prednisolone and radiotherapy. Vet Comp Oncol 2, 132-141. Dobson, J.M., Scase, T.J., 2007. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J Small Anim Pract 48, 424-431. Downing, S., Chien, M.B., Kass, P.H., Moore, P.E., London, C.A., 2002. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 63, 1718-1723. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C.L., 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031-1037. Du, C.Y., Shi, Y.Q., Zhou, Y., Fu, H., Zhao, G., 2008. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol 98, 175-178. Fosmire, S.P., Dickerson, E.B., Scott, A.M., Bianco, S.R., Pettengill, M.J., Meylemans, H., Padilla, M., Frazer-Abel, A.A., Akhtar, N., Getzy, D.M., Wojcieszyn, J., Breen, M., Helfand, S.C., Modiano, J.F., 2004. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 84, 562-572. Fox, L.E., Rosenthal, R.C., Twedt, D.C., Dubielzig, R.R., MacEwen, E.G., Grauer, G.F., 1990. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. J Vet Intern Med 4, 242-246. Frost, D., Lasota, J., Miettinen, M., 2003. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol 40, 42-54. Fulcher, R.P., Ludwig, L.L., Bergman, P.J., Newman, S.J., Simpson, A.M., Patnaik, A.K., 2006. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 228, 210-215. Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J.H., Ashman, L.K., Kanayama, Y., et al., 1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92, 1736-1744. Galli, S.J., Maurer, M., Lantz, C.S., 1999. Mast cells as sentinels of innate immunity. Curr Opin Immunol 11, 53-59. Galli, S.J., Nakae, S., 2003. Mast cells to the defense. Nat Immunol 4, 1160-1162. Galli, S.J., Nakae, S., Tsai, M., 2005. Mast cells in the development of adaptive immune responses. Nat Immunol 6, 135-142. Galli, S.J., Zsebo, K.M., Geissler, E.N., 1994. The kit ligand, stem cell factor. Adv Immunol 55, 1-96. Geissler, E.N., Ryan, M.A., Housman, D.E., 1988. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55, 185-192. Gibson, P.C., Cooper, K., 2002. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 9, 65-69. Giehl, K.A., Nagele, U., Volkenandt, M., Berking, C., 2007. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol 34, 7-14. Gil da Costa, R.M., Matos, E., Rema, A., Lopes, C., Pires, M.A., Gartner, F., 2007. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers. BMC Vet Res 3, 19. Ginn, P.E., Fox, L.E., Brower, J.C., Gaskin, A., Kurzman, I.D., Kubilis, P.S., 2000. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Vet Pathol 37, 33-39. Gleixner, K.V., Rebuzzi, L., Mayerhofer, M., Gruze, A., Hadzijusufovic, E., Sonneck, K., Vales, A., Kneidinger, M., Samorapoompichit, P., Thaiwong, T., Pickl, W.F., Yuzbasiyan-Gurkan, V., Sillaber, C., Willmann, M., Valent, P., 2007. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 35, 1510-1521. Govier, S.M., 2003. Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract 18, 103-106. Grant, I.A., Rodriguez, C.O., Kent, M.S., Sfilgoi, G., Gordon, I., Davis, G., Lord, L., London, C.A., 2008. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med 22, 388-393. Greer, K.A., Higgins, M.A., Cox, M.L., Ryan, T.P., Berridge, B.R., Kashtan, C.E., Lees, G.E., Murphy, K.E., 2006. Gene expression analysis in a canine model of X-linked Alport syndrome. Mamm Genome 17, 976-990. Gschwind, A., Fischer, O.M., Ullrich, A., 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4, 361-370. Hahn, K.A., King, G.K., Carreras, J.K., 2004. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998). J Am Vet Med Assoc 224, 79-82. Hahn, K.A., Ogilvie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P.S., Kinet, J.P., Palmerini, F., Dubreuil, P., Moussy, A., Hermine, O., 2008. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22, 1301-1309. Halaban, R., 2000. The regulation of normal melanocyte proliferation. Pigment Cell Res 13, 4-14. Halaban, R., Tyrrell, L., Longley, J., Yarden, Y., Rubin, J., 1993. Pigmentation and proliferation of human melanocytes and the effects of melanocyte-stimulating hormone and ultraviolet B light. Ann N Y Acad Sci 680, 290-301. Hanks, S.K., Quinn, A.M., Hunter, T., 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52. Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., Kiese, B., Eisenberg, B., Roberts, P.J., Singer, S., Fletcher, C.D., Silberman, S., Dimitrijevic, S., Fletcher, J.A., 2003. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21, 4342-4349. Henry, C.J., Downing, S., Rosenthal, R.C., Klein, M.K., Meleo, K., Villamil, J.A., Fineman, L.S., McCaw, D.L., Higginbotham, M.L., McMichael, J., 2007. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res 68, 1246-1251. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y., Kitamura, Y., 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580. Holgate, S.T., 2008. Pathogenesis of asthma. Clin Exp Allergy 38, 872-897. Hollenbeck, S.T., Sakakibara, K., Faries, P.L., Workhu, B., Liu, B., Kent, K.C., 2004. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J Surg Res 120, 288-294. Hosoya, K., Kisseberth, W.C., Alvarez, F.J., Lara-Garcia, A., Beamer, G., Stromberg, P.C., Couto, C.G., 2009. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc 45, 14-18. Hottendorf, G.H., Nielsen, S.W., 1967. Pathologic survey of 300 extirpated canine mastocytomas. Zentralbl Veterinarmed A 14, 272-281. Hottendorf, G.H., Nielsen, S.W., 1968. Pathologic report of 29 necropsies on dogs with mastocytoma. Pathol Vet 5, 102-121. Howard, E.B., Sawa, T.R., Nielsen, S.W., Kenyon, A.J., 1969. Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma. Pathol Vet 6, 146-158. Huang, E., Nocka, K., Beier, D.R., Chu, T.Y., Buck, J., Lahm, H.W., Wellner, D., Leder, P., Besmer, P., 1990. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63, 225-233. Huizinga, J.D., Thuneberg, L., Kluppel, M., Malysz, J., Mikkelsen, H.B., Bernstein, A., 1995. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373, 347-349. Huntley, J.F., 1992. Mast cells and basophils: a review of their heterogeneity and function. J Comp Pathol 107, 349-372. Isotani, M., Ishida, N., Tominaga, M., Tamura, K., Yagihara, H., Ochi, S., Kato, R., Kobayashi, T., Fujita, M., Fujino, Y., Setoguchi, A., Ono, K., Washizu, T., Bonkobara, M., 2008. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 22, 985-988. Izquierdo, M.A., Van der Valk, P., Van Ark-Otte, J., Rubio, G., Germa-Lluch, J.R., Ueda, R., Scheper, R.J., Takahashi, T., Giaccone, G., 1995. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol 177, 253-258. Jaffe, M.H., Hosgood, G., Taylor, H.W., Kerwin, S.C., Hedlund, C.S., Lopez, M.K., Davidson, J.R., Miller, D.M., Paranjpe, M., 2000. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Vet Pathol 37, 40-46. Jensen, B.M., Akin, C., Gilfillan, A.M., 2008. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol 154, 1572-1582. Kahler, C., Didlaukat, S., Feller, A.C., Merz, H., 2007. Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material. Diagn Pathol 2, 37. Kaldrymidou, H., Leontides, L., Koutinas, A.F., Saridomichelakis, M.N., Karayannopoulou, M., 2002. Prevalence, distribution and factors associated with the presence and the potential for malignancy of cutaneous neoplasms in 174 dogs admitted to a clinic in northern Greece. J Vet Med A Physiol Pathol Clin Med 49, 87-91. Kirshenbaum, A.S., Kessler, S.W., Goff, J.P., Metcalfe, D.D., 1991. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 146, 1410-1415. Kissel, H., Timokhina, I., Hardy, M.P., Rothschild, G., Tajima, Y., Soares, V., Angeles, M., Whitlow, S.R., Manova, K., Besmer, P., 2000. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J 19, 1312-1326. Kitamura, Y., Hirotab, S., 2004. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61, 2924-2931. Kitamura, Y., Tsujimura, T., Jippo, T., Kasugai, T., Kanakura, Y., 1995. Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. Int Arch Allergy Immunol 107, 54-56. Komuro, T., 1999. Comparative morphology of interstitial cells of Cajal: ultrastructural characterization. Microsc Res Tech 47, 267-285. Krause, D.S., Van Etten, R.A., 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353, 172-187. Kravis, L.D., Vail, D.M., Kisseberth, W.C., Ogilvie, G.K., Volk, L.M., 1996. Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs. J Am Vet Med Assoc 209, 1418-1420. Lamerato-Kozicki, A.R., Helm, K.M., Jubala, C.M., Cutter, G.C., Modiano, J.F., 2006. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol 34, 870-878. Lemmon, M.A., Ferguson, K.M., 2007. A new twist in the transmembrane signaling tool-kit. Cell 130, 213-215. Lemmon, M.A., Pinchasi, D., Zhou, M., Lax, I., Schlessinger, J., 1997. Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 272, 6311-6317. Letard, S., Yang, Y., Hanssens, K., Palmerini, F., Leventhal, P.S., Guery, S., Moussy, A., Kinet, J.P., Hermine, O., Dubreuil, P., 2008. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 6, 1137-1145. Lev, S., Blechman, J., Nishikawa, S., Givol, D., Yarden, Y., 1993. Interspecies molecular chimeras of kit help define the binding site of the stem cell factor. Mol Cell Biol 13, 2224-2234. London, C.A., Galli, S.J., Yuuki, T., Hu, Z.Q., Helfand, S.C., Geissler, E.N., 1999. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27, 689-697. London, C.A., Kisseberth, W.C., Galli, S.J., Geissler, E.N., Helfand, S.C., 1996. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol 115, 399-414. London, C.A., Malpas, P.B., Wood-Follis, S.L., Boucher, J.F., Rusk, A.W., Rosenberg, M.P., Henry, C.J., Mitchener, K.L., Klein, M.K., Hintermeister, J.G., Bergman, P.J., Couto, G.C., Mauldin, G.N., Michels, G.M., 2009. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 15, 3856-3865. London, C.A., Seguin, B., 2003. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 33, 473-489, v. Longley, B.J., Jr., Metcalfe, D.D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.Z., Heitjan, D., Ma, Y., 1999. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96, 1609-1614. Longley, B.J., Jr., Morganroth, G.S., Tyrrell, L., Ding, T.G., Anderson, D.M., Williams, D.E., Halaban, R., 1993. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 328, 1302-1307. Longley, B.J., Reguera, M.J., Ma, Y., 2001. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25, 571-576. Longley, B.J., Tyrrell, L., Lu, S.Z., Ma, Y.S., Langley, K., Ding, T.G., Duffy, T., Jacobs, P., Tang, L.H., Modlin, I., 1996. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12, 312-314. Lux, M.L., Rubin, B.P., Biase, T.L., Chen, C.J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C.D., Fletcher, J.A., 2000. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156, 791-795. Ma, Y., Longley, B.J., Wang, X., Blount, J.L., Langley, K., Caughey, G.H., 1999. Clustering of activating mutations in c-KIT''s juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 112, 165-170. Macy, D.W., 1985. Canine mast cell tumors. Vet Clin North Am Small Anim Pract 15, 783-803. Macy, D.W., 1986. Canine and feline mast cell tumors: biologic behavior, diagnosis, and therapy. Semin Vet Med Surg (Small Anim) 1, 72-83. Majumder, S., Brown, K., Qiu, F.H., Besmer, P., 1988. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol 8, 4896-4903. McCaw, D.L., Miller, M.A., Bergman, P.J., Withrow, S.J., Moore, A.S., Knapp, D.W., Fowler, D., Johnson, J.C., 1997. Vincristine therapy for mast cell tumors in dogs. J Vet Intern Med 11, 375-378. Metcalfe, D.D., 2005. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc 116, 185-203; discussion 203-184. Michels, G.M., Knapp, D.W., DeNicola, D.B., Glickman, N., Bonney, P., 2002. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc 38, 458-466. Miettinen, M., Lasota, J., 2001. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438, 1-12. Miettinen, M., Lasota, J., 2005. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13, 205-220. Miettinen, M., Sarlomo-Rikala, M., Lasota, J., 2000. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol 13, 536-541. Mizoguchi, M., 2004. Melanocyte development: with a message of encouragement to young women scientists. Pigment Cell Res 17, 533-544. Mizuki, M., Ueda, S., Matsumura, I., Ishiko, J., Schwable, J., Serve, H., Kanakura, Y., 2003. Oncogenic receptor tyrosine kinase in leukemia. Cell Mol Biol (Noisy-le-grand) 49, 907-922. Morini, M., Bettini, G., Preziosi, R., Mandrioli, L., 2004. C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. J Histochem Cytochem 52, 705-708. Mullins, M.N., Dernell, W.S., Withrow, S.J., Ehrhart, E.J., Thamm, D.H., Lana, S.E., 2006. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc 228, 91-95. Murphy, S., Sparkes, A.H., Blunden, A.S., Brearley, M.J., Smith, K.C., 2006. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec 158, 287-291. Murphy, S., Sparkes, A.H., Smith, K.C., Blunden, A.S., Brearley, M.J., 2004. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 154, 743-746. Naeem, M., Dahiya, M., Clark, J.I., Creech, S.D., Alkan, S., 2002. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 33, 1182-1187. Nagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tannenbaum, S., Suzuki, Y., Metcalfe, D.D., 1995. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92, 10560-10564. Nocka, K., Tan, J.C., Chiu, E., Chu, T.Y., Ray, P., Traktman, P., Besmer, P., 1990. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J 9, 1805-1813. Orfao, A., Garcia-Montero, A.C., Sanchez, L., Escribano, L., 2007. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 138, 12-30. Patnaik, A.K., Ehler, W.J., MacEwen, E.G., 1984. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 21, 469-474. Patnaik, M.M., Tefferi, A., Pardanani, A., 2007. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets 7, 492-503. Priester, W.A., 1973. Skin tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 50, 457-466. Rassnick, K.M., Bailey, D.B., Flory, A.B., Balkman, C.E., Kiselow, M.A., Intile, J.L., Autio, K., 2008. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med 22, 1390-1396. Rassnick, K.M., Moore, A.S., Williams, L.E., London, C.A., Kintzer, P.P., Engler, S.J., Cotter, S.M., 1999. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 13, 601-605. Ravandi, F., Talpaz, M., Estrov, Z., 2003. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res 9, 535-550. Reber, L., Da Silva, C.A., Frossard, N., 2006. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533, 327-340. Reguera, M.J., Rabanal, R.M., Puigdemont, A., Ferrer, L., 2000. Canine mast cell tumors express stem cell factor receptor. Am J Dermatopathol 22, 49-54. Riva, F., Brizzola, S., Stefanello, D., Crema, S., Turin, L., 2005. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest 17, 385-388. Ronnstrand, L., 2004. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61, 2535-2548. Rothwell, T.L., Howlett, C.R., Middleton, D.J., Griffiths, D.A., Duff, B.C., 1987. Skin neoplasms of dogs in Sydney. Aust Vet J 64, 161-164. Rubin, M.A., Kleter, B., Zhou, M., Ayala, G., Cubilla, A.L., Quint, W.G., Pirog, E.C., 2001. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159, 1211-1218. Sakuma, Y., Sakurai, S., Oguni, S., Hironaka, M., Saito, K., 2003. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 94, 486-491. Sasai, K., Katoh, M., Fujita, D., Yamashita, M., Constantinoiu, C.C., Matsubayashi, M., Tani, H., Baba, E., 2007. Monoclonal antibodies for the diagnosis of canine mastocytoma. Hybridoma (Larchmt) 26, 162-167. Satzger, I., Schaefer, T., Kuettler, U., Broecker, V., Voelker, B., Ostertag, H., Kapp, A., Gutzmer, R., 2008. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 99, 2065-2069. Scase, T.J., Edwards, D., Miller, J., Henley, W., Smith, K., Blunden, A., Murphy, S., 2006. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 20, 151-158. Seguin, B., Besancon, M.F., McCallan, J.L., Dewe, L.L., Tenwolde, M.C., Wong, E.K., Kent, M.S., 2006. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med 20, 933-940. Seguin, B., Leibman, N.F., Bregazzi, V.S., Ogilvie, G.K., Powers, B.E., Dernell, W.S., Fettman, M.J., Withrow, S.J., 2001. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc 218, 1120-1123. Sfiligoi, G., Rassnick, K.M., Scarlett, J.M., Northrup, N.C., Gieger, T.L., 2005. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001). J Am Vet Med Assoc 226, 1368-1374. Shelly, S.M., 2003. Cutaneous lesions. Vet Clin North Am Small Anim Pract 33, 1-46. Simmons, P.J., Aylett, G.W., Niutta, S., To, L.B., Juttner, C.A., Ashman, L.K., 1994. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp Hematol 22, 157-165. Simoes, J.P., Schoning, P., Butine, M., 1994. Prognosis of canine mast cell tumors: a comparison of three methods. Vet Pathol 31, 637-647. Simpson, A.M., Ludwig, L.L., Newman, S.J., Bergman, P.J., Hottinger, H.A., Patnaik, A.K., 2004. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 224, 236-240. Stanclift, R.M., Gilson, S.D., 2008. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 232, 53-62. Strohmeyer, T., Reese, D., Press, M., Ackermann, R., Hartmann, M., Slamon, D., 1995. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol 153, 511-515. Taylor, F., Gear, R., Hoather, T., Dobson, J., 2009. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. J Small Anim Pract 50, 284-289. Teske, E., Kirpensteijn, J., Rutteman, G.R., 2007. [A mastocytoma in a dog]. Tijdschr Diergeneeskd 132, 122-126. Thamm, D.H., Mauldin, E.A., Vail, D.M., 1999. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997). J Vet Intern Med 13, 491-497. Thamm, D.H., Turek, M.M., Vail, D.M., 2006. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 68, 581-587. Thamm, D.H., Vail, D.M., 2007. Aftershocks of cancer chemotherapy: managing adverse effects. J Am Anim Hosp Assoc 43, 1-7. Tsujimura, T., Furitsu, T., Morimoto, M., Isozaki, K., Nomura, S., Matsuzawa, Y., Kitamura, Y., Kanakura, Y., 1994. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 83, 2619-2626. Tsuura, Y., Hiraki, H., Watanabe, K., Igarashi, S., Shimamura, K., Fukuda, T., Suzuki, T., Seito, T., 1994. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 424, 135-141. Turrel, J.M., Kitchell, B.E., Miller, L.M., Theon, A., 1988. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc 193, 936-940. Ullrich, A., Schlessinger, J., 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203-212. Vandenbark, G.R., deCastro, C.M., Taylor, H., Dew-Knight, S., Kaufman, R.E., 1992. Cloning and structural analysis of the human c-kit gene. Oncogene 7, 1259-1266. Webster, J.D., Yuzbasiyan-Gurkan, V., Kaneene, J.B., Miller, R., Resau, J.H., Kiupel, M., 2006. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 8, 104-111. Webster, J.D., Yuzbasiyan-Gurkan, V., Miller, R.A., Kaneene, J.B., Kiupel, M., 2007. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol 44, 298-308. Webster, J.D., Yuzbasiyan-Gurkan, V., Thamm, D.H., Hamilton, E., Kiupel, M., 2008. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res 4, 32. Wedemeyer, J., Tsai, M., Galli, S.J., 2000. Roles of mast cells and basophils in innate and acquired immunity. Curr Opin Immunol 12, 624-631. Wehrle-Haller, B., 2003. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 16, 287-296. Weiss, R.R., Whitaker-Menezes, D., Longley, J., Bender, J., Murphy, G.F., 1995. Human dermal endothelial cells express membrane-associated mast cell growth factor. J Invest Dermatol 104, 101-106. Weisse, C., Shofer, F.S., Sorenmo, K., 2002. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc 38, 71-73. Welle, M.M., Bley, C.R., Howard, J., Rufenacht, S., 2008. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 19, 321-339. Went, P.T., Dirnhofer, S., Bundi, M., Mirlacher, M., Schraml, P., Mangialaio, S., Dimitrijevic, S., Kononen, J., Lugli, A., Simon, R., Sauter, G., 2004. Prevalence of KIT expression in human tumors. J Clin Oncol 22, 4514-4522. Willmore-Payne, C., Holden, J.A., Tripp, S., Layfield, L.J., 2005. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36, 486-493. Yarden, Y., Kuang, W.J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T.J., Chen, E., Schlessinger, J., Francke, U., Ullrich, A., 1987. Human proto-oncogene c-
摘要: 犬肥大細胞瘤生物特性非常的多樣化,以至於臨床難以評估其預後,目前被認為是一種惡性腫瘤且最終可導致病犬的死亡。犬肥大細胞瘤大部分病程發展快速易轉移至淋巴結,且外科切除後易復發。臨床上,九成以上病犬可藉由細針抽取的方式被診斷出來,但目前卻鮮少文獻有犬肥大細胞瘤細胞學與其預後之間相關性的研究。目前KIT被認為是造成犬肥大細胞瘤的致病因子。本次研究目的主要是建立完整的細胞學與組織學在不同染色上做分級制度來與預後存活期間等做一個完整個評估,藉由了解KIT蛋白位置、KIT表現強度、c-kit基因突變方式與其他臨床病理學因子在犬肥下胞瘤分化及預後方面等是否有其相關性。細胞學以DQ與WG染色,組織學以H&E與Toluidine blue兩種染色;免疫組織化學染色的方式來看KIT 位置與表現強度;另一方面也會抽取腫瘤細胞的RNA經反轉錄酶的作用轉錄成cDNA,再利用PCR技術將c-kit基因片段放大之後定序。研究結果發現細胞學與組織學分級、KIT蛋白位置與其他臨床病理學因子具有顯著相關性且其存活期間具有顯著差異。KIT蛋白位於異常位置時,細胞學與組織學的分級會越高,表腫瘤分化越不良、區域淋巴結及遠端腫瘤轉移率、臨床分期等也會增加,腫瘤團塊大於五公分顯示其預後皆不良。分級越高的腫瘤其c-kit基因點突變的機率也越高,不同的治療方式也會影響其存活時間。根據我們實驗結果,認為細胞學、組織學與KIT表現位置皆可作為犬肥大細胞瘤的獨立預後因子來評估病犬的存活時間。完整的細胞學分級制度希望不只可以提供門診一個快速方便又費用低的診斷方式,也及時提供蓄主病犬的預後狀況。藉由了解KIT蛋白的表現位置與c-kit突變方式希望可以找到一個更有效的方法來治療犬肥大細胞瘤,提高病犬的生活品質。
The biological behavior of canine mast cell tumors (MCTs) is highly variable and often difficult to predict, often have an aggressive behavior that may result in death of the patient. Canine MCTs develop quickly, are rapid to metastasize, and frequently recur after having been removed. Recently, KIT has been implicated in the pathogenesis of canine cutaneous MCTs. The aims of our study were to investigate clinical presentation, establishment of a cytologic grading including the characteristics of Diff-Quik and Wright-Giemsa staining smears patterns observed on fine needle cytology, histological grading in haematoxylin and eosin and toluidine blue stains, KIT in canine MCTs in terms of KIT protein localization and KIT expression levels by immunohistochemical staining and the cDNA of the region encoding c-kit was amplified and sequenced to explore the mutation of c-kit. Results showed that clinicopathologic findings were significantly correlated with KIT immunostaining expression or c-kit mutations in poorly differentiated MCTs. Canine MCTs with aberrant protein localization of KIT, KIT overexpression or deletion mutations of c-kit was positive correlated with the higher histological grade and the decreased survival time. Therefore, clinical staging, regional metastasis, cytopathologic findings and histological grading were important for prognostic prediction in dogs with MCTs. These results might explore the role of KIT in the pathogenesis of higher grade MCTs and provided to predict behavior of canine MCTs for the successful treatment of this neoplastic disease.
URI: http://hdl.handle.net/11455/14257
其他識別: U0005-2008201015354700
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-2008201015354700
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.